[1]
A. Blauvelt, J. F. Fowler, Jr., E. Schuck, J. Jauch, H. Woehling, and C. L. Leonardi, “A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis”, J of Skin, vol. 1, no. 3.1, p. s29, Oct. 2017.